检索范围:
排序: 展示方式:
null
《医学前沿(英文)》 2017年 第11卷 第4期 页码 449-461 doi: 10.1007/s11684-017-0589-5
In recent years, unexpected outbreaks of infectious diseases caused by emerging and re-emerging viruses have become more frequent, which is possibly due to environmental changes. These outbreaks result in the loss of life and economic hardship. Vaccines and therapeutics should be developed for the prevention and treatment of infectious diseases. In this review, we summarize and discuss the latest progress in the development of small-molecule viral inhibitors against highly pathogenic coronaviruses, including severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, Ebola virus, and Zika virus. These viruses can interfere with the specific steps of viral life cycle by blocking the binding between virus and host cells, disrupting viral endocytosis, disturbing membrane fusion, and interrupting viral RNA replication and translation, thereby demonstrating potent therapeutic effect against various emerging and re-emerging viruses. We also discuss some general strategies for developing small-molecule viral inhibitors.
关键词: emerging and re-emerging viruses small-molecule inhibitor coronavirus Ebola virus Zika virus life cycle
Human monoclonal antibodies as candidate therapeutics against emerging viruses
null
《医学前沿(英文)》 2017年 第11卷 第4期 页码 462-470 doi: 10.1007/s11684-017-0596-6
The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.
关键词: human monoclonal antibodies emerging infectious diseases SARS-CoV MERS-CoV Ebola virus
Removal of virus aerosols by the combination of filtration and UV-C irradiation
《环境科学与工程前沿(英文)》 2023年 第17卷 第3期 doi: 10.1007/s11783-023-1627-y
● The removal of virus aerosols by filtration and UV-C irradiation was proposed.
关键词: Filtration system UV-C irradiation Virus aerosol Public health COVID-19
Ying HUANG, Clement Wesley GNANADURAI, Zhenfang FU
《农业科学与工程前沿(英文)》 2017年 第4卷 第3期 页码 260-267 doi: 10.15302/J-FASE-2016116
关键词: antiviral blood brain barrier chemokines and cytokines innate immunity rabies virus
Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection:
null
《医学前沿(英文)》 2017年 第11卷 第4期 页码 480-489 doi: 10.1007/s11684-017-0594-8
Superinfection is frequently detected among individuals infected by human immunodeficiency virus type I (HIV-1). Superinfection occurs at similar frequencies at acute and chronic infection stages but less frequently than primary infection. This observation indicates that the immune responses elicited by natural HIV-1 infection may play a role in curb of superinfection; however, these responses are not sufficiently strong to completely prevent superinfection. Thus, a successful HIV-1 vaccine likely needs to induce more potent and broader immune responses than those elicited by primary infection. On the other hand, potent and broad neutralization responses are more often detected after superinfection than during monoinfection. This suggests that broadly neutralizing antibodies are more likely induced by sequential immunization of multiple different immunogens than with only one form of envelope glycoprotein immunogens. Understanding why the protection from superinfection by immunity induced by primary infection is insufficient and if superinfection can lead to cross-reactive immune responses will be highly informative for HIV-1 vaccine design.
关键词: human immunodeficiency virus type I superinfection incidence immune response
Regulation of exogenous bFGF gene mediated by recombinant adeno-associated virus
Ke SONG, Nianjing RAO, Meiling CHEN, Yingguang CAO
《医学前沿(英文)》 2009年 第3卷 第2期 页码 158-163 doi: 10.1007/s11684-009-0042-5
关键词: tetracycline regulatory system adeno-associated virus basic fibroblast growth factor gene regulation
Advances in newly developing therapy for chronic hepatitis C virus infection
null
《医学前沿(英文)》 2014年 第8卷 第2期 页码 166-174 doi: 10.1007/s11684-014-0334-2
Chronic hepatitis C virus (HCV) infection afflicts a reported 170 million people worldwide and is often complicated by cirrhosis and hepatocellular carcinoma. Morbidity and mortality are decreased with the successful treatment of chronic HCV infection. Increased understanding of the HCV has allowed further development of new direct-acting antiviral (DAA) agents against the HCV and has also allowed the development of IFN-free oral treatment regimens. In late 2013 the first nucleotide polymerase inhibitor regimen with RBV alone for genotypes 2/3 and in combination with a 12-week regimen of PEG-IFN+RBV for genotypes 1, 4 was approved for use in the US. A number of promising new DAA regimens which are IFN-free are in phase 3 development and the first will likely be approved for use in the US in 2014. The currently approved regimens are discussed in detail and currently available data on future regimens are reviewed herein.
关键词: direct-acting antiviral (DAA) nucleotide polymerase inhibitors protease inhibitors
null
《医学前沿(英文)》 2017年 第11卷 第4期 页码 471-479 doi: 10.1007/s11684-017-0602-z
Several universal influenza virus vaccine candidates based on eliciting antibodies against the hemagglutinin stalk domain are in development. Typically, these vaccines induce responses that target group 1 or group 2 hemagglutinins with little to no cross-group reactivity and protection. Similarly, the majority of human anti-stalk monoclonal antibodies that have been isolated are directed against group 1 or group 2 hemagglutinins with very few that bind to hemagglutinins of both groups. Here we review what is known about the human humoral immune response to vaccination and infection with H7 subtype influenza viruses on a polyclonal and monoclonal level. It seems that unlike vaccination with H5 hemagglutinin, which induces antibody responses mostly restricted to the group 1 stalk domain, H7 exposure induces both group 2 and cross-group antibody responses. A better understanding of this phenomenon and the underlying mechanisms might help to develop future universal influenza virus vaccine candidates.
关键词: universal influenza virus vaccine hemagglutinin stalk H7N9
Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection
Weibao Song, Hongjuan Zhang, Yu Zhang, Rui Li, Yanxing Han, Yuan Lin, Jiandong Jiang
《医学前沿(英文)》 2021年 第15卷 第3期 页码 404-415 doi: 10.1007/s11684-021-0834-9
关键词: Zika virus clinical drugs ZIKV inhibitors antivirals repurposing
Claudia DOEL,Zhidong ZHANG,Lise MAZELET,Ryan WATERS,John BASHIRUDDIN
《农业科学与工程前沿(英文)》 2014年 第1卷 第3期 页码 250-257 doi: 10.15302/J-FASE-2014031
Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China
null
《医学前沿(英文)》 2014年 第8卷 第2期 页码 135-144 doi: 10.1007/s11684-014-0331-5
Chronic hepatitis B is a major health problem in China. The universal vaccination program since 1992 has changed the epidemiology of hepatitis B virus infection in China from highly to moderately endemic. The most prevalent hepatitis B virus strains in China are genotypes B and C, whereas those in western provinces are genotypes D and C/D hybrid. Chronic hepatitis B poses a heavy burden to the society in China. Different treatment strategies have been explored to improve patient outcomes in a cost-effective manner. However, antiviral drugs with a low genetic barrier to resistance are still extensively used because of the generally low income and limited resources in China. Individualized antiviral therapy is closely associated with translational medicine, which utilizes information from studies on genomics, immune biomarkers, and fibrosis. The results of these studies are crucial in further improving treatment outcomes.
MicroRNAs and hepatitis viruses
Gang LI MD , Xiaojia XIONG MM ,
《医学前沿(英文)》 2009年 第3卷 第3期 页码 265-270 doi: 10.1007/s11684-009-0055-0
Yulu Wang, Dan Hu, Yanling Wu, Tianlei Ying
《医学前沿(英文)》 2020年 第14卷 第2期 页码 149-159 doi: 10.1007/s11684-020-0764-y
关键词: influenza virus neutralizing antibody hemagglutinin globular head region trimeric interface
Clinical significance of human papilloma virus infection in the cervical lesions
Shuang LI, Yu-Han MENG, Hu TING, Jian SHEN, Ding MA
《医学前沿(英文)》 2010年 第4卷 第3期 页码 264-270 doi: 10.1007/s11684-010-0094-6
关键词: cervical lesion high risk-human papilloma virus persistent infection loading dose cervical intraepithelial neoplasia cervical cancer
Genome editing for the treatment of tumorigenic viral infections and virus-related carcinomas
Lan Yu, Xun Tian, Chun Gao, Ping Wu, Liming Wang, Bei Feng, Xiaomin Li, Hui Wang, Ding Ma, Zheng Hu
《医学前沿(英文)》 2018年 第12卷 第5期 页码 497-508 doi: 10.1007/s11684-017-0572-1
Viral infections cause at least 10%–15% of all human carcinomas. Over the last century, the elucidation of viral oncogenic roles in many cancer types has provided fundamental knowledge on carcinogenetic mechanisms and established a basis for the early intervention of virus-related cancers. Meanwhile, rapidly evolving genome-editing techniques targeting viral DNA/RNA have emerged as novel therapeutic strategies for treating virus-related carcinogenesis and have begun showing promising results. This review discusses the recent advances of genome-editing tools for treating tumorigenic viruses and their corresponding cancers, the challenges that must be overcome before clinically applying such genome-editing technologies, and more importantly, the potential solutions to these challenges.
关键词: genome-editing tools tumorigenic virus delivery method off-target effect virus-related carcinoma
标题 作者 时间 类型 操作
Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses
null
期刊论文
Critical roles of chemokines and cytokines in antiviral innate immune responses during rabies virus infection
Ying HUANG, Clement Wesley GNANADURAI, Zhenfang FU
期刊论文
Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection:
null
期刊论文
Regulation of exogenous bFGF gene mediated by recombinant adeno-associated virus
Ke SONG, Nianjing RAO, Meiling CHEN, Yingguang CAO
期刊论文
Universal influenza virus vaccines: what can we learn from the human immune response following exposure
null
期刊论文
Repurposing clinical drugs is a promising strategy to discover drugs against Zika virus infection
Weibao Song, Hongjuan Zhang, Yu Zhang, Rui Li, Yanxing Han, Yuan Lin, Jiandong Jiang
期刊论文
Dynamics of foot-and-mouth disease virus replication in cells at different phases of the cell-division
Claudia DOEL,Zhidong ZHANG,Lise MAZELET,Ryan WATERS,John BASHIRUDDIN
期刊论文
Recent advances in “universal” influenza virus antibodies: the rise of a hidden trimeric interface in
Yulu Wang, Dan Hu, Yanling Wu, Tianlei Ying
期刊论文
Clinical significance of human papilloma virus infection in the cervical lesions
Shuang LI, Yu-Han MENG, Hu TING, Jian SHEN, Ding MA
期刊论文